USSTOCK.TODAY
Market Closed
Log in Sign up

Aptevo Therapeutics Inc. Announces Preclinical Data Showing Potential to Overcome Immune Suppression in Solid Tumors

ACCESSWIRE +1 · ·by G4L

APVO
APVO Aptevo Therapeutics Inc
$1.13 -8.87%
View chart & analysis →
  1. 1Aptevo Therapeutics Inc. presented new preclinical data for its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026.
  2. 2Aptevo confirmed results promoting tumor cell death even within immunosuppressive environments through three experimental molecules.
  3. 3APVO451 and APVO452 are expected to advance as Investigational New Drug (IND)-enabling studies in 2027.

So what's the key point?

Aptevo Therapeutics Inc. presented new preclinical data for its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026.

Source ACCESSWIRE +1 · View original ↗

Related 3-line summaries

Aptevo Therapeutics Announces Substantial Reduction in Mipretamig-Related Infusion Reactions ACCESSWIRE +1 · 3d agoAptevo Reports 93% Clinical Benefit Rate with Mipleta... Triple Combo in TP53-Mutant AML ACCESSWIRE +1 · Sep 3Sphere 3D Releases Q2 Results and Business Update Following Cathedra Merger Newsfile +1 · Aug 14
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news